Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine

Vaccine

Volumn 19, Issue 4-5, 2000, Pages 460-469

  Chabalgoity, Jose A ^a   Moreno, María ^a   Carol, Hernan ^a   Dougan, Gordon ^b   Hormaeche, Carlos E ^c  

^a Dept Biotech Inst Hyg Avda A   (Uruguay)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; LIVE VACCINE; TETANUS TOXIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOG; ECHINOCOCCUS GRANULOSUS; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SALMONELLA TYPHIMURIUM; STRAIN DIFFERENCE; VACCINE PRODUCTION;

ADMINISTRATION, ORAL; ANIMAL; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; BASE SEQUENCE; DNA PRIMERS; DOG DISEASES; DOGS; ECHINOCOCCOSIS; ECHINOCOCCUS; GENES, BACTERIAL; IMMUNOGLOBULIN G; IN VITRO; LYMPHOCYTE ACTIVATION; SALMONELLA TYPHIMURIUM; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0034668157     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00197-3     Document Type: Article

References (44)

1. Hormaeche C.E., Khan C.M.A., Mastroeni P., Villareal B., Dougan G., Chatfield S.N. Salmonella vaccines: mechanisms of immunity and their use as carriers of recombinant antigens. Ala'Aldeen D., Hormaeche C.E. Molecular and clinical aspects of vaccine development. 1995;119-153 Wiley, New York.
2. Roberts M., Chatfield S.N., Dougan G. Salmonella as carriers of heterologous antigens. O'Hagan D.T. Novel delivery system for oral vaccines. 1994;27-58 CRC Press, Boca Raton, FL.
3. Black R.E., Levine M.M., Clements M.L., Losonsky G., Herrington D., Berman S., Formal S.B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 155:1987;1260-1265.
4. Chatfield S.N., Fairweather N., Charles I., Pickard D., Levine M., Hone D., Posada M., Strugnell R.A., Dougan G. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine. 10:1992;53-60.
5. Gonzalez C.R., Noriega F.R., Huerta S., Santiago A., Vega M., Paniagua J., Ortiz- Navarrete V., Isibasi A., Levine M.M. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine. 16:1998;1043-1052.
6. Herrington D.A., Van-de-Verg L., Formal S.B., Hale T.L., Tall B.D., Cryz S.J., Tramont E.C., Levine M.M. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 8:1990;353-357.
7. Sztein M.B., Tanner M.K., Polotsky Y., Orenstein J.M., Levine M.M. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:1995;3987-3993.
8. Sztein M.B., Wasserman S.S., Tacket C.O., Edelman R., Hone D., Lindberg A.A., Levine M.M. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunised with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170:1994;1508-1517.
9. Tacket C.O., Levine M.M. Typhoid vaccines old and new. Ala'Aldeen D., Hormaeche C.E. Molecular and clinical aspects of vaccine development. 1995;155-178 Wiley, New York.
10. Tacket C.O., Forrest B., Morona R., Attridge S.R., LaBrooy J., Tall B.D., Reymann M., Rowley D., Levine M.M. Safety, immunogenicity and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 8:1990;1620-1627.
11. Tacket C.O., Hone D.M., Curtiss III R., Kelly S.M., Losonsky G., Guers L., Harris A.M., Edelman R., Levine M.M. Comparison of the safety and immunogenicity of ΔaroC and ΔaroD and Δcya, Δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:1992;536-541.
12. Tacket C.O., Hone D.M., Losonsky G.A., Guers L., Edelman R., Levine M.M. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine. 10:1992;443-446.
13. Tacket C.O., Kelly S.M., Schodel F., Losonsky G., Nataro J.P., Edelman R., Levine M.M., Curtiss R. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65:1997;3381-3385.
14. Gonzalez C., Hone D., Noriega F.R., Tacket C.O., Davis J.R., Losonsky G., Nataro J.P., Hoffman S., Malik A., Nardin E. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169:1997;927-931.
15. van-de-Verg L., Herrington D.A., Murphy J.R., Wasserman S.S., Formal S.B., Levine M.M. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect. Immun. 58:1990;2002-2004.
16. Villarreal-Ramos B., Manser J., Collins R.A., Dougan G., Chatfield S.N., Howard C.J. Immune responses in calves immunised orally or subcutaneously with a live Salmonella typhimurium aro vaccine. Vaccine. 16:1998;45-54.
17. d'Oliveira C., Feenstra A., Vos H., Osterhaus A.D., Shiels B.R., Cornelissen A.W., Jongejan F. Induction of protective immunity to Theileria annulata using two major merozoite surface antigens presented by different delivery systems. Vaccine. 15:1997;1796-1804.
18. Gentschev I., Glaser I., Goebel W., McKeever D.J., Musoke A., Heussler V.T. Delivery of the p67 sporozoite antigen of Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle. Infect. Immun. 66:1998;2060-2064.
19. Heussler V.T., Taracha E.L., Musoke A., Duchateau L., McKeever D.J. Immunization with live attenuated Salmonella dublin expressing a sporozoite protein confers partial protection against Theileria parva. Vaccine. 16:1998;834-841.
20. Smith B.P., Reina-Guerra M., Hoiseth S.K., Sotcker B.A.D., Habasha F., Johnson E., Merritt F. Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Amer. J. Vet. Res. 45:1984;59-66.
21. Stabel T.J., Mayfield J.E., Morfitt D.C., Wannemuehler M.J. Oral immunization of mice and swine with an attenuated Salmonella choleraesuis [Dcya-12 D(crp-cdt)19] mutant containing a recombinant plasmid. Infect. Immun. 61:1993;610-618.
22. Thompson R.C.A. Biology and systematics of Echinococcus. Thompson R.C.A., Lymbery A.J. Echinococcus and Hydatid disease. 1995;1-50 CAB International, Wallingfords.
23. Cohen H., Paolillo E., Bonifacino R., Botta B., Parada L., Cabrera P., Snowden K., Gasser R., Tessier R., Dibarboure L., Wen H., Allan J.C., Soto de Alfaro H., Rogan M.T., Craig P.S. Human cystic echinococcosis in a Uruguayan community: a sonographic, serologic, and epidemiologic study. Am. J. Trop. Med. Hyg. 59:1998;620-627.
24. Heath D.D. Immunology of Echinococcus infections. Thompson R.C.A., Lymbery A.J. Echinococcus and Hydatid disease. 1995;183-199 CAB International, Wallingfords.
25. Morse E.V., Duncan M.A. Canine salmonellosis: prevalence, epizootiology, signs, and publich health significance. J. Am. Vet. Med. Assoc. 167:1975;817-820.
26. Sato Y., Kuwamoto R. A case of canine salmonellosis due to Salmonella infantis. J. Vet. Med. Sci. 61:1999;71-72.
27. Estevez A., Dallagiovanna B., Ehrlich R. A developmentally regulated gene of Echinococcus granulosus codes for a 15.5 kDa polypeptide related to fatty acid binding proteins. Mol. Biochem. Parasitol. 58:1993;215-222.
28. Tendler M., Vilar M.M., Brito C.A., Freire N.M.S., Katz N., Simson A. Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14 - potential basis of a multivalent anti helminth vaccine. Memorias do Instituto Oswaldo Cruz. 90:1995;255-256.
29. Chabalgoity J.A., Harrison J.A., Esteves A., Demarco de Hormaeche R., Ehrlich R., Khan C.M.A., Hormaeche C.E. Expression and immunogenicity of an Echinococcus granulosus fatty acid binding protein in live attenuated salmonella vaccine strains. Infect. Immun. 65:1997;2402-2412.
30. Miller V.L., Mekalanos J.J. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J. Bacteriol. 170:1988;2575-2583.
31. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. 1989;Cold Spring Harbor, Laboratory Press, New York.
32. Khan C.M.A., Villareal-Ramos B., Pierce R.J., Riveau G., Hormaeche R.D., McNeill H., Ali T., Fairweather N., Chatfield S., Capron A., Dougan G., Hormaeche C.E. Construction, expression and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA. 91:1994;11261-11265.
33. Charles I.G., Lamb H.K., Pickard D., Dougan G., Hawkins A.R. Isolation, characterization and nucleotide sequences of the aroC genes encoding chorismate synthase from Salmonella typhi and Escherichia coli. J. Gen. Microb. 136:1990;353-358.
34. Villarreal B., Mastroeni P., Demarco de Hormaeche R., Hormaeche C.E. Proliferative and T-cell specific interleukin (IL-2/IL-4) production responses in spleen cells from mice vaccinated with aroA live attenuated Salmonella vaccines. Micro. Path. 13:1992;305-315.
35. Stabel T.J., Mayfield J.E., Tabatabai L.B., Wannemuehler M.J. Swine immunity to an attenuated Salmonella typhimurium mutant containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus. Infect. Immun. 59:1991;2941-2947.
36. Tijhar E.J., Siebelink K.H.J., Karlas J.A., Burger M.C., Mooi F.R., Osterhaus A.D.M.E. Induction of feline immunodeficiency virus specific antibodies in cats with an attenuated Salmonella strain expressing the Gag protein. Vaccine. 15:1997;587-596.
37. Gottstein B., Muller N., Cryz S.J., Vogel M., Tanner I., Seebeck T. Humoral and cellular immune responses in mice and dogs induced by a recombnant Echinococcues multimlocularis antigen produced by a Salmonella typhimurium vaccine strain. Parasite Immunol. 12:1990;163-174.
38. Covone M.G., Brocchi M., Palla E., Dias da Silveira W., Rappuoli R., Galeotti C.L. Levels of expression and immunogenicity of attenuated Salmonella enterica serovar Typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect. Immun. 66:1998;224-231.
39. Schödel F., Milich D.R., Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated salmonellae for oral vaccination. J. Immunol. 145:1990;4317-4321.
40. VanCott J.L., Staats H.F., Pascual D.W., Roberts M., Chatfield S.N., Yamamoto M., Coste M., Carter P.B., Kiyono H., McGhee J.R. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1996;1504-1514.
41. Xu D., Mcsorley S.J., Chatfield S.N., Dougan G., Liew F.Y. Protection against Leishmania major infection in genetically sysceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-). Immunology. 85:1995;1-7.
42. Yang D.M., Fairweather N., Button L.L., McMaster W.R., Kahl L.P., Liew F.Y. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 145:1990;2281-2285.
43. Deplazes P., Smith N.C., Arnold P., Lutz H., Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 17:1995;451-458.
44. Nieto C.G., Garcia-Alonso M., Requena J.M., Miron C., Soto M., Alonso C., Navarrete I. Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet. Immunol. Immunopathol. 67:1999;117-130.